Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: A matched case-control study

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 134-1339

  Cho, Hye Yon ^a   Kyung, Min Sun ^a  

^a Hallym University   (South Korea)

Author keywords

Biological; CA 19 9 antigen; Cystadenoma; Mucinous; Ovary; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HUMAN; HUMAN TISSUE; MEDICAL RECORD REVIEW; OVARY TUMOR; PATHOLOGY; QUANTITATIVE ASSAY; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SAMPLING; TUMOR VOLUME; ADENOCARCINOMA, MUCINOUS; BLOOD; MIDDLE AGED; OVARIAN NEOPLASMS; RISK;

ADENOCARCINOMA, MUCINOUS; ADULT; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84905177651     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890954     Document Type: Article

References (39)

1. Pavai S, Yap SF: The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia, 2003; 58: 667-72
2. Scharl A, Crombach G, Vierbuchen M et al: Antigen CA 19-9: presence in mucosa of nondiseased mullerian duct derivatives and marker for differentiation in their carcinomas. Obstet Gynecol, 1991; 77: 580-85
3. Dede M, Gungor S, Yenen MC et al: CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer, 2006; 16: 189-93
4. Wang WS, Lin JK, Chiou TJ et al: CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology, 2002; 49: 160-64
5. Ni XG, Bai XF, Mao YL et al: The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol, 2005; 31: 164-69
6. Fong ZV, Winter JM: Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J, 2012; 18: 530-38
7. Kyung MS, Choi JS, Hong SH et al: Elevated CA 19-9 levels in mature cystic teratoma of the ovary. Int J Biol Markers, 2009; 24: 52-56
8. Kelly PJ, Archbold P, Price JH et al: Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol, 2010; 63: 169-73
9. Berek JS, Bast RC Jr: Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 1995; 76: 2092-96
10. Bast RC Jr, Klug TL, St John E et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 1983; 309: 883-87
11. Gadducci A, Ferdeghini M, Prontera C et al: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol, 1992; 44: 147-54
12. Zorn KK, Tian C, McGuire WP et al: The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer, 2009; 115: 1028-35
13. Lu D, Kuhn E, Bristow RE et al: Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol, 2011; 122: 560-66
14. Rosen DG, Wang L, Atkinson JN et al: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005; 99: 267-77
15. Kelly PJ, Archbold P, Price JH et al: Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol, 2010; 63(2): 169-73
16. Hart WR: Mucinous tumors of the ovary: a review. Int J Gynecol Pathol, 2005; 24: 4-25
17. Landen CN Jr, Birrer MJ, Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol, 2008; 26: 995-1005
18. Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004; 164: 1511-18
19. Koshiyama M, Matsumura N, Konishi I: Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int, 2014; 2014: 934261
20. Kurman RJ, Shih Ie M: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol, 2011; 42(7): 918-31
21. Santin AD, Zhan F, Bellone S et al: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer, 2004; 112: 14-25
22. Salani R, Kurman RJ, Giuntoli R II et al: Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer, 2008; 18: 487-91
23. Cho KR, Shih Ie M: Ovarian cancer. Annu Rev Pathol, 2009; 4: 287-313
24. International Collaborative Ovarian Neoplasm G: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 2002; 360: 505-15
25. Mackay HJ, Brady MF, Oza AM et al: Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer, 2010; 20: 945-52
26. Naik JD, Seligmann J, Perren TJ: Mucinous tumours of the ovary. J Clin Pathol, 2012; 65: 580-84
27. Lalwani N, Shanbhogue AK, Vikram R et al: Current update on borderline ovarian neoplasms. Am J Roentgenol, 2010; 194: 330-36
28. Hart WR, Norris HJ: Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer, 1973; 31: 1031-45
29. Rodriguez IM, Prat J: Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol, 2002; 26: 139-52
30. Ma FH, Zhao SH, Qiang JW et al: MRI appearances of mucinous borderline ovarian tumors: Pathological correlation. J Magn Reson Imaging, 2014 [Epub ahead of print]
31. Vargas HA, Barrett T, Sala E: MRI of ovarian masses. J Magn Reson Imaging, 2013; 37: 265-81
32. Bent CL, Sahdev A, Rockall AG et al: MRI appearances of borderline ovarian tumours. Clin Radiol, 2009; 64: 430-38
33. Bazot M, Haouy D, Darai E, et al: Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours? Clin Radiol, 2013; 68: e1-8
34. Donaldson ES, van Nagell JR Jr, Pursell S et al: Multiple biochemical markers in patients with gynecologic malignancies. Cancer, 1980; 45: 948-53
35. Karaferic A, Jovanovic D, Jelic S: Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. J BUON, 2009; 14: 635-39
36. Ito K: CA19-9 in mature cystic teratoma. Tohoku J Exp Med, 1994; 172: 133-38
37. Emin U, Tayfun G, Cantekin I et al: Tumor markers in mature cystic teratomas of the ovary. Arch Gynecol Obstet, 2009; 279: 145-47
38. Cho HY, Kim K, Jeon YT et al: CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer-CA19-9 level in teratoma. Med Sci Monit, 2013; 19: 230-35
39. Yamashita K, Watanabe M: Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci, 2009; 100: 195-99